Page 1 | Search Results | Hematology, ASH Education Program

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Scherber RM, Mesa RA. Managing myelofibrosis (MF) that “blasts” through: advancements in the treatment of relapsed/refractory and blast-phase MF. Hematology Am Soc Hematol Educ Program . 2018;2018:118-126.

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 630.

https://doi.org/10.1182/hematology.201900100

Published: 2019

Journal Articles

Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome

Jibran Durrani, Jaroslaw P. Maciejewski

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 97–104.

https://doi.org/10.1182/hematology.2019000019

Published: 2019

Journal Articles

Mechanisms of and approaches to overcoming resistance to immunotherapy

Liora Schultz, Rebecca Gardner

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 226–232.

https://doi.org/10.1182/hematology.2019000018

Published: 2019

Journal Articles

Antibody-based therapies in patients with acute lymphoblastic leukemia

Shira Dinner, Michaela Liedtke

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 9–15.

https://doi.org/10.1182/asheducation-2018.1.9

Published: 2018

Journal Articles

Managing myelofibrosis (MF) that “blasts” through: advancements in the treatment of relapsed/refractory and blast-phase MF

Robyn M. Scherber, Ruben A. Mesa

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 118–126.

https://doi.org/10.1182/asheducation-2018.1.118

Published: 2018

Journal Articles

MRD in AML: does it already guide therapy decision-making?

Gert Ossenkoppele, Gerrit Jan Schuurhuis

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 356–365.

https://doi.org/10.1182/asheducation-2016.1.356

Published: 2016

Journal Articles

Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs)

Naveen Pemmaraju, Ruben Mesa

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 649–651.

https://doi.org/10.1182/asheducation-2015.1.649

Published: 2015

Journal Articles

Do somatic mutations in de novo MDS predict for response to treatment?

Mark A. Schroeder, Amy E. DeZern

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 317–328.

https://doi.org/10.1182/asheducation-2015.1.317

Published: 2015

Journal Articles

Minimal residual disease in acute myeloid leukemia: coming of age

Elisabeth Paietta

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 35–42.

https://doi.org/10.1182/asheducation.V2012.1.35.3797926

Published: 2012

Journal Articles

Malignant or benign leukocytosis

Tracy I. George

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 475–484.

https://doi.org/10.1182/asheducation.V2012.1.475.3798515

Published: 2012

Journal Articles

Novel Antibody-Based Therapies For Acute Lymphoblastic Leukemia

Dieter Hoelzer

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 243–249.

https://doi.org/10.1182/asheducation-2011.1.243

Published: 2011

Journal Articles

High Cytogenetic or Molecular Genetic Risk Acute Myeloid Leukemia

Elihu Estey

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 474–480.

https://doi.org/10.1182/asheducation-2010.1.474

Published: 2010

Journal Articles

Prognosis of Myelodysplastic Syndromes

Guillermo Garcia-Manero

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 330–337.

https://doi.org/10.1182/asheducation-2010.1.330

Published: 2010

Journal Articles

Evidence-Based Mini-Review: Should Patients Over the Age of 60 with INT-2 or High-Risk Myelodysplastic Syndrome Undergo Allogeneic Stem Cell Transplantation Prior to Progression to Acute Myelogenous Leukemia?

Mark A. Schroeder, William Blum

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 322–324.

https://doi.org/10.1182/asheducation-2010.1.322

Published: 2010

Journal Articles

The Biology of Acute Promyelocytic Leukemia and Its Impact on Diagnosis and Treatment

Francesco Lo-Coco, Emanuele Ammatuna

Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 156–161.

https://doi.org/10.1182/asheducation-2006.1.156

Published: 2006

Journal Articles

Treatment of the 5q– Syndrome

Pierre Fenaux, Charikleia Kelaidi

Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 192–198.

https://doi.org/10.1182/asheducation-2006.1.192

Published: 2006

Journal Articles

New Developments in the Therapy of Acute Myelocytic Leukemia

Norbert C. Gorin, Elihu Estey, Richard J. Jones, Hyam I. Levitsky, Ivan Borrello, Shimon Slavin

Hematology Am Soc Hematol Educ Program (2000) 2000 (1): 69–89.

https://doi.org/10.1182/asheducation.V2000.1.69.69

Published: 2000

Journal Articles

Morphology Glossary

James R. McArthur, M.D.

Hematology Am Soc Hematol Educ Program (2000) 2000 (1): 457–474.

https://doi.org/10.1182/asheducation.V2000.1.457.457

Published: 2000

NARROW

Scherber RM, Mesa RA. Managing myelofibrosis (MF) that “blasts” through: advancements in the treatment of relapsed/refractory and blast-phase MF. Hematology Am Soc Hematol Educ Program . 2018;2018:118-126.

Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome

Mechanisms of and approaches to overcoming resistance to immunotherapy

Antibody-based therapies in patients with acute lymphoblastic leukemia

Managing myelofibrosis (MF) that “blasts” through: advancements in the treatment of relapsed/refractory and blast-phase MF

MRD in AML: does it already guide therapy decision-making?

Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs)

Do somatic mutations in de novo MDS predict for response to treatment?

Minimal residual disease in acute myeloid leukemia: coming of age

Malignant or benign leukocytosis

Novel Antibody-Based Therapies For Acute Lymphoblastic Leukemia

High Cytogenetic or Molecular Genetic Risk Acute Myeloid Leukemia

Prognosis of Myelodysplastic Syndromes

Evidence-Based Mini-Review: Should Patients Over the Age of 60 with INT-2 or High-Risk Myelodysplastic Syndrome Undergo Allogeneic Stem Cell Transplantation Prior to Progression to Acute Myelogenous Leukemia?

The Biology of Acute Promyelocytic Leukemia and Its Impact on Diagnosis and Treatment

Treatment of the 5q– Syndrome

New Developments in the Therapy of Acute Myelocytic Leukemia

Morphology Glossary

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only